阿帕替尼联合替吉奥二线治疗胃癌患者对CA19-9、CEA、TSGF水平的影响  

Effect of Apatinib Combined with Tiggio on the Levels of CA19-9,CEA and TSGF in Patients with Gastric Cancer

作　　者：艾良[1] 张麒[1] AI Liang,ZHANG Qi.(Tumor Hospital of Yunnan,Kunming,65010)

机构地区：[1]云南省肿瘤医院,650100

出　　处：《实用癌症杂志》2018年第4期541-543,共3页The Practical Journal of Cancer

摘　　要：目的评价阿帕替尼联合替吉奥二线治疗胃癌患者对CA19-9、CEA、TSGF水平的影响,以及观察其疗效和不良反应。方法选择60例二线治疗及二线以上的胃癌患者,随机分为对照组和试验组,各30例。对照组患者给予口服替吉奥治疗,试验组患者给予阿帕替尼联合替吉奥治疗,两组患者以4周为1个化疗周期,根据患者个人身体情况,最多接受3个化疗周期。比较两组患者不同化疗周期后的血清CA19-9、CEA、TSGF的水平,同时观察并比较两组患者治疗期间的近期疗效及不良反应情况。结果治疗后阿帕替尼联合替吉奥治疗组患者总缓解率为36.70%,疾病控制率为76.70%,明显高于只给予替吉奥组患者组的总缓解率23.33%,疾病控制率为50.00%,差异具有统计学意义(P<0.05);3个疗程过后,试验组患者CA19-9、CEA、TSGF水平明显低于对照组,差异具有统计学意义(P<0.05);试验组相对于对照组,发生不良反应例数显著减少,特别是胃肠道反应和肝功能损伤,差异具有统计学意义(P<0.05)。结论阿帕替尼联合替吉奥二线治疗胃癌患者,可有效缓解病情的发展,不良反应轻微可控制,具有较大的临床应用价值,值得在临床中推广应用。Objective To evaluate the effect of apatinitil combined with tiggio on the levels of CA19-9, CEA and TSGF in patients with gastric cancer,and to observe the curative effect and adverse reactions. Methods From January 2015 to Decem- ber 2016,60 patients with second- line treatment and more than two- stage gastric cancer were randomly divided into control group and experimental group. Patients in the control group were treated with oral tiggio, and the patients in the trial group were treated with apotinib combined with tiggio. The patients in the two groups were treated with a cycle of 4 weeks and received up to three cycles based on the patient~ physical condition. The levels of serum CA19-9, CEA and TSGF in the two groups were compared, and the short-term curative effect and adverse reaction were observed and compared between the two groups. Results After treat- ment, the total remission rate was 36.70% and the control rate was 76.70% in the treatment group, and the total remission rate was 23.33% （ P 〈 0.05 ）. The levels of CA19-9, CEA and TSGF in the experimental group were significantly lower than those in the control group （ P 〈 0.05 ）. Compared with the control group, the number of adverse reactions was significantly decreased, espe- cially the gastrointestinal tract and liver function injury （P 〈 O. 05 ）. Conclusion Apotipine combined with tiggloxis in the treat- ment of gastric cancer can effectively relieve the development of the disease. Adverse reactions can be controlled slightly and have great clinical value. It is worthy to be popularized in clinical practice.

关 键 词：阿帕替尼 替吉奥 胃癌 CA19—9 CEA TSGF 

分 类 号：R735.2[医药卫生—肿瘤]